Plain-English translation of NCT06523465 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Primary aldosteronism is a condition where your body makes too much of a hormone called aldosterone, which causes high blood pressure that's hard to control. This trial compares three different medication combinations—one using Simvastatin with amlodipine, another combining Simvastatin with spironolactone and amlodipine, and a third pairing spironolactone with amlodipine—to see which works best at lowering blood pressure and reducing your long-term heart risk.
Current treatments for primary aldosteronism are limited and don't always prevent heart problems in the long run. Researchers want to find out whether adding Simvastatin (a cholesterol medication) to standard treatments might help protect your heart better.
You likely qualify if…
You likely don't qualify if…
You'll be randomly assigned to take one of three medication combinations for 6 months. During this time, you'll visit the clinic for regular check-ups where doctors will measure your blood pressure, take blood and urine samples to check your hormone and kidney function, and monitor how well the treatment is working. The study will track how your condition improves and whether the medication combination reduces your risk of future heart problems.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China